The administration of I: 2-diphenyl-3: 5-dioxo-4-n-butylpyrazolidine (Butazolidin, Phenylbutazone) to patients with various rheumatic disorders appears to be followed by clinical improvement in a large proportion of cases (Currie, 1951 (Currie, , 1953 ; Kuzell and others, 1952; Steinbrocker and others, 1952; Stephens and others, 1952 ; Davies and others, 1952) . Although at present the mode of action of this drug remains unknown, it has been claimed to be an "anti-arthritic" and "anti-rheumatic" agent. The meaning of such terms would seem to be obscure in our present state of knowledge. No evidence has been produced that it acts via the pituitary-adrenal axis. Suggestions that Butazolidin is a more potent analgesic in rheumatic disease than in other painful conditions are not supported by more than clinical impressions: the assessment of the comparative effects of analgesics is extremely difficult. Steinbrocker and his colleagues (1952) , in a blindfold clinical trial, concluded that its analgesic effect was greater than that of salicylates or amidopyrine in rheumatic conditions.
The clinical trials quoted were carried out on relatively large groups of patients and little detailed information is available as to the precise effects of Butazolidin on the various potentially reversible phenomena of rheumatoid arthritis. The present report describes a more detailed study of the effect of this drug on a small group of patients, using for comparison ACTH, a substance whose effect in reversing many of the clinical features of rheumatoid arthritis is well recognized. It would clearly be desirable to compare the effect of simple analgesics such as aspirin in the same manner, but such trials are time-onsuc ing for the patient and this has not so far been possible. The difficulties of measuring the various features of rheumatoid arthritis are great. Clearly, no more than an approximation can be attempted in comparing the effects of two different agents.
Methods
Six patients with active rheumatoid arthritis, considere to have sufficient reversible features to enable therapeutic effects to be measured, were admitted to hospital. After a period of bed rest to allow a reasonably static state to be achieved (at least 2 weeks), they were treated with ACTH and Butazolidin. It was intended, from the longterm point of view, to treat these patients with Butazolidin, but it was felt desirable to compare the effects of ACTH and Butazolidin first, in order to obtain some assessment as to the suitability of Butazolidin for longterm treatment. In three cases ACTH was administered first, and in three cases Butazolidin first.
Dosage.-ACTH was given intramuscularly in divided doses of 100 mg./24 hrs for at least 5 days, the dose then being gradually tapered off to avoid, as far as possible, a rebound relapse. Butazolidin was given orally in doses of 600 to 800 mg./24 hrs for a minimum of 10 days. No other specific treatment was given.
Tests.-Features selected for measurement at regular intervals throughout the trial were as follows:
Erythrocyte sedimentation rate (Westergren), (Kellgren and others, 1952 Particulars of the six patients with whom these experiments were carried out are shown in Table I . (Table IV) .
Results Erythrocyte Sedimentation Rate (Table I1 ).-The mean erythrocyte sedimentation rate before ACTH treatment was 64 mm./hr (Westergren), and before Butazolidin it was 59 mm./hr (Table II) . During ACTH administration it fell to a mean of 35 mm., and during Butazolidin it fell to a mean of 52 mm./hr; the change occurring during ACTH administration is statistically significant (t= 5 373, P <001). That occurring during Butazolidin therapy does not reach significance (t=0-775, P>0 05). This does not, of course, necessarily indicate that Butazolidin has no effect on the erythrocyte sedimentation rate. It indicates that the experiment is sufficiently sensitive in this respect to demonstrate the wellestablished effect of ACTH on the erythrocyte sedimentation rate in this disease, but offers no evidence that Butazolidin does as has been claimed by Currie (1952) . The fall in erythrocyte sedimentation rate associated with this latter drug was much less than that produced by ACTH and within the limits which could occur by chance alone. The mean erythrocyte sedimentation rate during the interval between trials was 2 mm. lower than at the beginning. The mean fall during Butazolidin therapy was only 7 mm., which reinforces the suggestion that Butazolidin itself has no more effect than that which may be produced by rest in bed. (2) Joint Tenderness.- Table VI shows the changes that occurred in joint tenderness during the trial; in both cases a diminution is recorded during treatment of a comparable degree. The "total tenderness" before treatment with either substance is approximately the same, and the change in both cases is significant (for ACTH, t=4 613, P<0*01; for Butazolidin, t=4 523, P<001). Practically complete relapse (95 per cent.) was achieved in this test; ACTH reduced the joint tenderness to 62 per cent. of pre-treatment levels, and Butazolidin to 57 per cent. (1) The response to the two drugs differs in that: ACTH produces a fall in erythrocyte sedimentation rate, a rise in 17-ketosteroid and glucocorticoid excretion, and a diminution in joint swelling, whereas Butazolidin cannot be shown to have any effect on the erythrocyte sedimentation rate in this experiment; it has either no effect, or a depressing effect, on 17-ketosteroid and glucocorticoid excretion, and no effect on joint swelling.
(2) When subjective effects are assessed (though of necessity in an arbitrary manner), both drugs seem to have roughly the same effect.
(3) Both drugs also appear to have a comparable effect on function tests.
Although there is no evidence as to the effect of analgesics when assessed in this way, it would seem that Butazolidin has no effect which cannot be produced by an analgesic, at least over the short period in which it was administered in this trial. There is no evidence that it has a cortisone-like effect; it is impossible to judge from these tests whether it has an "anti-inflammatory" action, although the lack of evidence of diminution in joint swelling when administered for a short period does not suggest that it has. It must be emphasized that this study was in no way directly concerned with the use of either substance as practical therapy and that these observations were made simply on the short-term effects of the drugs on a few potentially reversible phenomena of rheumatoid arthritis. Nor was this study concerned with the anti-pyretic or toxic effects of either substance. No 
